* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download 313-1A (1)
NK1 receptor antagonist wikipedia , lookup
Discovery and development of tubulin inhibitors wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Discovery and development of non-nucleoside reverse-transcriptase inhibitors wikipedia , lookup
Discovery and development of direct Xa inhibitors wikipedia , lookup
Discovery and development of proton pump inhibitors wikipedia , lookup
Discovery and development of neuraminidase inhibitors wikipedia , lookup
Pharmacognosy wikipedia , lookup
Psychopharmacology wikipedia , lookup
Drug interaction wikipedia , lookup
Discovery and development of integrase inhibitors wikipedia , lookup
Discovery and development of angiotensin receptor blockers wikipedia , lookup
Neuropharmacology wikipedia , lookup
Discovery and development of beta-blockers wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Discovery and development of ACE inhibitors wikipedia , lookup
Text books 1. Wilson and Gisvold’s Textbook of Organic Medicinal and Pharmaceutical Chemistry, J.N.Delgado and W.A.Remers eds., 11th edition, Lippincott-Raven, Philadelphia, (2004). 2. Lemeke, T. L. and Williams, D. A., Foye’s Principle of Medicinal Chemistry, Lippincott Williams & Wilkins, Philadelphia, PA., 6th Edition, (2008).) 1 Cardiovascular Drugs are those of Cardiovascular drugs: are those used for prevention or treatment of cardiovascular diseases diseases Cardiovascular drugs: are grouped according to their therapeutic application into the following categories: 1- Antianginal Drugs - Coronary Vasodilators 2- Antihypertensive Agents 3- Antiarrhythmic Agents 4- Drugs used in Congestive Heart Failure 5- Anti-hyperlipidemic Agents 6- Anticoagulants 2 1. Antianginal Drugs - Coronary Vasodilators Angina pectoris is the disease of the coronary artery, the principal supplier of blood carrying oxygen from the left ventricle to all heart tissues including the ventricles themselves. Angina is the principal symptom of an ischemic heart. It is characterized by a sudden, severe pain originating in the chest, radiating through the left shoulder and running down the arm. The symptom has been described since 1772 Anti-anginal drugs mainly alleviate and prevent anginal attacks by dilating the coronary artery. Such action replenishes the left ventricle tissues of fresh blood carrying oxygen and relieves anginal pain. 3 • Three classes of drugs are found to be efficient in this regard: 1.1. Organic nitrates. 1.2. Calcium channels blockers. 1.3. β-Adrenergic blockers. 1.1. Organic Nitrates (Nitrovasodilators) They are esters of simple organic alcohols or polyols with nitric acid. This class was developed after the anti-anginal effect of amyl nitrite was first observed in 1857. They include: Amyl nitrite: Mixture of isomeric amyl nitrite but principally isoamyl nitrite Nitroglycerin: Glyceryl Trinitrate Erythrityl tetranitrate Isosorbide dinitrate: 1,4:3,6-Dianhydro-D-glucitol dinitrate Pentaerythritol 4 tetranitrate tetranitrate: 2,2-bis(hydroxymethyl)-1,3-propandiol Except for amyl nitrite, all are nitrate esters (R-ONO2). 5 Structure Nitrate Esters RO H + alcohol RO H alcohol + HO N O RO N O nitrous acid alkyl nitrite + HO N _ O nitric acid O + RO N + H2O water _ O O alkyl nitrate + H2O water • Some nitrate esters are wrongly named, e.g., amylnitrite is actually isoamylnitrite, nitroglycerin is not a nitro compound • Nitrate esters are susceptible to hydrolysis! Shelf life is a concern. 6 The chemistry of these molecule is easily predicted based on the structures presented above as follow: i. They are small molecules ii. They all are non-polar. iii. They are ester derivatives with susceptible C-O bond. This leads to ease of hydrolysis. Thus moisture should be avoided to minimize the loss in principal active component. iv. They are nitrate esters, therefore these compounds may be explosive, especially in pure concentrated form. Thus these compounds should be packaged in variety of diluents with excipients . v. The number of nitrate ester groups may vary from two to more than four, however, there is no direct relationship between them. number of nitrate groups and the level of activity. vi. The higher the lipophilicity of the drug, the greater the 7 potency and the longer the vasodilatory response. vii. The structure of the organic nitrates determines the onset and duration of action as shown in the following table: 8 Pharmacokinetics of Nitrate Esters Amyl nitrite Onset (min) 0.25 Duration of Action (min) Nitroglycerin 2 30 Isosorbide dinitrate 3 60 Erythrityl tetranitrate 15 180 Pentaerythritol tetranitrate 20 330 Metabolites 1 Active • Nitrite esters act fast! Think about the size of these molecules. • They are rapidly metabolized in the liver (glutathione-nitrate reductase). Yet, can be used in oral prophylactic therapy. • Number of nitrate groups does not linearly correspond to potency • Nitrate esters and possibility of explosion! • 9 Nitrovasodilators decrease the blood pressure of patients!! Synthesis of isosorbide dinitrate: CH2OH CHO H HO H OH H H2/pt HO H H OH H OH H OH H OH CH2OH OH OH CH2OH H2SO4 H O ONO2 O H HNO3 H2SO4 OH H O O H ONO2 1,4:3,6-Dianhydro-D-glucitol dinitrate 10 Metabolism Organic nitrates are metabolized rapidly after oral administration, they generate nitric oxide (NO) in situ that forms the basis of their pharmacological action. The mechanism of release of NO from nitrites and nitrates is not clear. Mechanism of Action Nitric oxide has been shown to be an important messenger in many signal transduction processes. This free radical gas is naturally produced endogenously from arginine in a complete reaction that is catalyzed by nitric oxide synthetase (NOS). 11 12 1.2. Calcium Channel Blockers Calcium channel blockers available for anti-anginal action are heterogeneous group of compounds. On the basis of structural features three main subgroups can be differentiated: 1.2.1. Phenylalkylamines Verapamil and Bepridil 1.2.2. Dihydropyridines Nifedipine and others 1.2.3. Benzothiazipines Diltiazem 1.2.1. Phenylalkylamines They are structurally characterized by central basic nitrogen to which alkyl and aralkyl groups are attached. Representative example for this class is Bepridil and Verapamil 13 NOR: ~20% Active CH3 MeO N CH3 CH3 MeO O-deMe gives inactive species – Verapamil is a synthetic CN MeO OMe Verapamil N Ph CH3 O N compound possessing structural similarity to papaverine. It is a chiral compound where the (+)isomer is more potent than the (-)-isomer as a calcium channel blocker. CH3 Bepridil – The essential structural features of this class of drugs are: The benzene ring. A 3ry amino nitrogen, which is almost completely charged at physiological pH. iii. The isopropyl group is not essential for activity. i. ii. 14 1.2.2. The 1,4-dihydropyridines. The 1,4-dihydropyrines form a rather extensive group of calcium channel antagonists. They are possessing the following general R1 structure: R2 H H3CO2C H3C CO2R3 N H CH2R4 R1 R2 R3 R4 Generic Name H NO2 H Cl H NO2 C2H5 CH2CH2N(CH3)CH2Ph CH3 OCH2CH2NH2 H H Amlodipine Nicardipine Nifedipine Nifedipine: Dimethyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl) pyridine-3,5-dicarboxylate. 15 Synthesis: It is synthesized by condensation of 2 mol of methylacetoacetate with 1 mol each of ammonia and 2-nitrobenzaldehyde. NH3 O + O H N O O O + O O O H O H NO2 16 O O NO2 The structural features essential for activity are : 1. The 1,4-dihydropyridine ring 2. The 2ry nitrogen in the ring which remains uncharged at physiological pH. 3. A bulky substituent (almost phenyl) in the 4 position of dihydropyridine. 4. Nitro group and ester moieties are not essential. X Extensive hydroxylation to inactive species R' R'' R''' R' Nifedipine NO2 CH3 H COOR'' Amlodipine Cl C2H5 O-(CH2)2-NH2 Nicardipine H -(CH2)2-N(CH3)(CH2-Ph) H H3COOC H3C N H 17 CH2R''' X H X NO2 1.2.3. Benzothiazepines Diltiazem 3ry The basic nitrogen is essential for activity. N-demethyl derivative as well as quaternization products are either less active or not active compared to the parent compound. O H H S O N N O CH3 H3C Diltiazem 18 CH3 Des-Ac gives ~50% Protein Binding of Calcium Channel Blockers Protein Binding Duration of Action Metabolites Amlodipine >95% 24 h phenyl hydroxylations, inactive Diltiazem ~80% 6 h iv desacetyl derivative, ~ 50 % active Bepridil >90% 24 h Verapamil 90% 8h 19 Extensive inactive metabolites N-demethyl derivative, ~ 20 % active Biochemical Mechanism of Action 20 Metabolism First-pass metabolism occurs extensively, especially for verapamil, leading to low bioavailability. The primary metabolites are N-demethylated and deacetylated products. These metabolites are inactive. The duration of action of these calcium channel blockers ranges from 4 - 8 h. However, amlodipine and Bipridil is the only agent that is active over a 24 h range. Why? 21 1.3. -Adrenergic blockers Nonselective Blockers HO N H Propranolol O 1-Isopropylamino-3-(1-naphthyloxy)-propan-2-ol – It is the prototype non-selective competitive antagonist at both 1 and 2 receptors. – Relatively high lipid solubility allows distribution to the CNS (some drowsiness) 22 Synthesis: NH2 O Propranolol + Cl O OH Naphthol O Epichlorohydrine Major Metabolites: HO N H HO COOH O O 23 OH 4-Hydroxy propranolol (Potant -blocker) Naphthoxylactic acid Nonselective antagonists 1-Selective antagonists Propranolol Metoprolol Nadolol Atenolol Timolol Esmolol Pindolol Acebutalol Labetolol Carvedilol 24 Selective 1 Blockers (Cardioselective) O N H OH Atenolol NH2 O – It is the prototype Selective 1 Blocker – Its half-life is twice that of propranolol – It is used in hypertension, angina pectoris associated with coronary atherosclerosis and acute myocardial infarction. 25 • Atenolol also differs from propranolol in that only a small amount (6%-16%) is bound to proteins in the plasma 26 Esmolol O N H OH O O – Very rapid onset & short duration of action (WHY?) – 1-selective – Used as IV infusion for pri-operative tachycardia and hypertension, arrhythmias – Used in electroconvulsive therapy 27 2. Antihypertensive Agents Agents Used to Treat Hypertension: 28 What is Hypertension? • A serious disease affecting 1 in 3 adults in the United States • More commonly known as High Blood Pressure http://www.beauregard.org/bldpress.htm 29 • Occurs when blood is forced through the heart and arteries under excessive pressure What is Blood Pressure? • Blood pressure readings have two components: – Systolic pressure • Heart muscles contracted – Diastolic pressure • Heart muscles relaxed • With hypertension: – Arteries narrow thereby increasing pressure – Fluid volume in arteries increases which can increase pressure 30 http://www.everybody.co.nz/page-3f71418a-d1e1-43d7-9ac0-fdcb4a79a3e3.aspx Classifying Blood Pressure by Readings Blood Pressure Category Systolic (mm Hg) Diastolic (mm Hg) Normal <120 <80 Prehypertension 120-139 80-89 High: Stage 1 140-159 90-99 High: Stage 2 160 + 100 + • High Blood Pressure = Elevated systolic pressure and/or elevated diastolic pressure • The highest reading dictates classification • Elevated readings must occur on multiple occasions to be diagnosed 31 Classifying Hypertension by Causes • Primary or Essential Hypertension – 90-95% of hypertension cases – Causes are unknown, but linked to risk factors • Secondary Hypertension – 5-10% of hypertension cases – Caused by disease states • Some causes include: kidney disease, atherosclerosis, hormone imbalances, pregnancy, and some medications 32 Risk Factors • Controllable Alcohol use Excess sodium Lack of exercise Stress Smoking Obesity due to inactivity/overeating – Medications – – – – – – 33 • Uncontrollable Age Race Gender Family history Medical condition Obesity due to medical condition – Medications – – – – – – Who is Affected by Hypertension? • Affects 1 billion people worldwide • Affects 65 million Americans age 6+ • 30% of people with hypertension don’t know they have it Race and Gender 34 Prevalence White Female 19.3% Race and Gender White Male 24.4% White Males 14.4% African-American Female 34.2% African-American Males 49.6% African-American Male 35.0% White Females 13.7% Hispanic Female 22.0% African-American Females 40.5% Hispanic Male 25.2% Death Rate (Death rates per 100,000 people) Why Should I Care? • Hypertension can elevate your risk for: – Stroke • Blood clots • Bleeding – – – – – 35 Heart attacks Heart enlargement Heart failure Kidney failure Atherosclerosis http://member.rivernet.com.au/balehirs/drHt2.jpg Treatment Options for Hypertension • Normal blood pressure cases: – Prevent hypertension • Reduction of controllable risk factors • Prehypertension cases: – Reduction of controllable risk factors – Careful monitoring • Stage 1 & Stage 2 hypertension cases: – Reduction of controllable risk factors – Close monitoring – Drug therapies 36 Available Drug Therapies • Drug therapies available: – – – – – – – – – 37 ACE (angiotensin-converting enzyme) inhibitors Alpha blockers Alpha-2-agonists Angiotensin II receptor blockers Beta blockers Calcium channel blockers Combined alpha and beta blockers Combined ACE inhibitors and diuretics Diuretics 2. Antihypertensive Agents The available antihypertensive drugs can be classified on the basis of their mechanism of action as follows: 2.1. Sympathetic Depressant Agents 2.1.1. Centrally acting agents. 2.1.2. Agents with both central and peripheral actions. 2.1.3. Ganglionic blocking agents. 2.1.4. β-adrenergic blocking agents. 2.1.5. α-adrenergic blocking agents 2.1.6. Combined α-and β-adrenergic blocking agents 2.1.7. Agents that block catecholamine synthesis 38 2.1.1. Centrally acting agents. Methyldopa HO It is postulated that αmethylnorepinehrine, (αmethyldopa metabolite) lowers arterial pressure by stimulating central adrenoreceptors which causes a reduction in sympathetic nervous outflow. NH2 HO CH2 C CO2H CH3 3-Hydroxy--methyl-Ltyrosine Clonidine Cl N H N N Cl 39 H It stimulates the central a– adrenoreceptors which lead to inhibition of central sympathetic tone, resulting in a lowering of arterial pressure and of heart rate. The renin-angiotensin system of blood pressure control 40 41 2.2. Angiotensin Converting Enzyme (ACE) Inhibitors Angiotensinogen Renin Angiotensin I Inactive decapeptide ACE (dipeptidyl carboxypeptidase) Angiotensin II Octapeptide (A very potent vasoconstrictor) – ACE inhibitors inactivate angiotensin–converting enzyme (ACE) thereby preventing the formation of peptides angiotensin II and III, agents that mediate the signal for increasing the systemic blood pressure. 42 The first substance developed in this sense was Teprotide, a nonapeptide isolated from the venom of Bothrops jararaca. With the recognition that ACE was a metallo-enzyme, inhibitors of ACE had been developed. Captopril It is the first orally active ACE inhibitor, used in severe essential and renovascular hypertension. However it introduces some side effects such as rashes and loss of taste. 1-(3-mercapto-2-methyl-oxopropyl)-L-proline 43 Interaction of ACE with the normal substrate 44 Inhibition of ACE with Captopril Hydrophobic pocket Hydrophobic pocket Vacant CH3 CH3 EXTENSION N O O N H Binding site 45 O O (I) CO2 N N H Binding site O O CO2 Lisinopril H2 N HO 2C H H , 2 H 2O N N H O H CO2 H N-[N-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl]-L-proline – It is a lysine derivative of enaliprilate, see next, nonthiol-containing ACE inhibitor. Like all ACE inhibitors it is an active site-directed inhibitor of the enzyme using the Zn ion in an effective binding interaction at a stoichiometeric ratio of 1:1. 46 ACE Inhibitor Prodrugs Enalapril Maleate H3C O O H H CH3 CO2 H O N H N , CO2 H CO2 H H 1-[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-L-proline . Maleate It is a long acting ACE inhibitor (prodrug), it requires activation by hydrolysis of its ethyl ester to form the diacid of enaliprilate. 47 Fosinopril Sodium OCOC2H5 H O N P O O H CO2Na It is a phosphorus – containing ACE inhibitor. It is inactive but serves as a prodrug, being completely hydrolyzed by intestinal and liver enzymes to the active diacid Fosinoprilate. 48 General characters of ACE Produrgs 1. They are non-thiol-containing ACE inhibitors devoid of the side effects of rashes and loss of taste seen with captopril. 2. It is interesting to observe that the loss in affinity caused by the replacement of the mercapto function by a carboxyl rest was compensated with the help of additional hydrophobic interaction. 49 3. With the exception of the phosphorus-containing Fosinopril, they have a 2-(S)- aminophenylbutyric acid ethyl ester moiety differing only in the substituents on the amino group. 4. They have the common property of acting as prodrugs, being hydrolyzed by intestinal and liver enzymes to the active di-acid. 5. They are used, as the prototype drug Captopril, in the treatment of mild to moderate hypertension. 50 2.2.2. Angiotensin II Antagonists Inhibition of Angiotensin II to produce a vasoconstrictor effect can be achieved by administration of competitive antagonists such as Saralasin. The newly introduced class of hypotensive drugs known as Sartans. Cl Losartan N N OH N N K N N It is an orally active non-peptidic hypotensive agent acting through its high affinity for Angiotensin II receptor sites of the smooth muscles, kidney and adrenal glands. It does not inhibit ACE, therefore avoiding the serious side effects of ACE inhibitors. 51 Olmesartan Medoxomil H3C OH H3C It was introduced to market in 2002 in the US as an orally administered treatment for hypertension. It is rapidly and completely bioactivated by ester hydrolysis to its active metabolite, Olmesartan, thus it is an ester prodrug of Olmesartan. H3C N O N N N O N NH O O CH3 O H3C OH H3C H3C H3C OH N H3C O N N N O H3C N N O NH Hydrolysis N OH O O O CH3 Olmesartan Medoxomil 52 N N Olmesartan N NH Olmesartan is a new selective and competitive non-peptide angiotensin II type 1 (AT1) receptor antagonist and potentially inhibits the Ang.II-induced pressor responses. Olmesartan Medoxomil was also shown to reduce blood pressure significantly more effectively than losartan and the ACE inhibitor captopril and as effectively as the β–blocker atenolol. 53 2.3. Direct-Acting Vasodilators Hydralazine. HCl It lowers arterial pressure in many experimental models of hypertension. It acts on vascular smooth muscle to cause relaxation, however, its precise mechanism of action is still controversial. NHNH2 N .HCl N 1-Hydrazinophthalazine Essential structure requirements necessary for maximal activity are: 1. The presence of a free amino group. 2. Position of the hydrazino-group in phthalazine moiety (position 1) is optimal for duration of action. 3. Unsubstituted phthalazine moiety, substitution of phthalazine or its replacement with other nucleus (e.g. pyridine or benzene) greatly affect the activity. 54 Sodium Nitroprusside CN + [Na ]2 NC ON Fe CN CN .2H2O CN Pentakis(cyano-C)nitrosylferrate(II) disodium dihydrate – It is one of the most potent blood pressure lowering drugs, its use is limited to hypertensive emergencies due to its short duration of action. –The hypotensive effect of the drug is due to the formation of NO in situ, elevating cellular levels of cGMP. – Thiocyanate is the final metabolic product Nitroprusside and to which the toxicity is attributed. 55 of Sodium Potassium Channel Agonists – They called “potassium channel openers”. They activate ATPsensitive potassium channel, which leads to a decrease of intracellular Ca+ and reduces the excitability of smooth muscle. – The primary action of these drugs is to open potassium channels in the plasma membrane of vascular smooth muscle. An efflux of potassium from the cell follows, resulting in hyperpolarization of the membrane that produces an inhibitory influences on membrane excitation and subsequent vasodilation. 56 Diazoxide O Cl Cl N O S NH NH H2NO2S S O O N CH3 7-Chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide • It is a des-sulfamoyl analogue of the benzothiazine diuretics and has a close structural similarity to chlorothiazide. • It was developed intentionally to increase the antihypertensive action of the thiazides and to minimize the diuretic effect. • It is used as sodium salt by i.v. injection as rapidly acting hypotensive drug for emergency reduction of blood pressure. 57 H2N Minoxidil N 6-(piperidin-1-yl)pyrimidine-2,4-diamine 3-oxide O N N H2N It is the only direct-acting vasodilator that requires metabolic activation to produce hypotensive effect. It is converted to minoxidil sulfate in the liver by a sulfotransferase enzyme. N N Sulfotransferase N H 2N N N O 58 NH2 H2N N OSO3 NH2 Selective 1-Blockers O Acyl moiety Quinazoline ring H3CO N N R N Piprazine ring N H3CO R Gen. Name NH2 Prazosin O Terazosin O O Doxazosin O 59 Clinical Uses: – Hypertension – Benign prostatic hypertrophy - reverses smooth muscle contraction 60 3. Antiarrhythmic Agents They are classified into 4 classes based on their mechanism of action or pattern of electrophysiological effects produced on heart tissue. 61 A representation of the membrane action potential. Phase 0 corresponds to rapid depolarization (inward movement of Na+ ions), while phases 1 through 4 are repolarizations through movement of K+, Ca+2 and Cl- ions. Repolarization is completed during phase 4, the resting phase. The duration of action potential is the total time for 0-3 segment. 62 Phase 0: The permeability of the membrane for sodium ions increases , and sodium rapidly inters the cells causing them to become depolarized Phase 1: Reduce the rate of sodium influx but favors the influx of chloride and efflux of potassium. Phase 2: the plateau phase, results from slow inward movement of calcium and efflux of potassium that balances the influx of calcium Thus resulting in little or no change in membrane potential. Phase 3: slowing the calcium influx coupled with a continued efflux of Potassium. Phase 4: Continued efflux of potassium from the cell restores the membrane potential to normal resting potential levels. During phase 4, Na+, K+-ATPase pump restores the ions to their proper local concentrations. 63 64 3.1. Class I: Sodium Channel Blockers All class I antiarrhythmic agents (Ia, Ib and Ic) decrease the rate of rise (upstrocke velocity) of phase 0 of the action potential by inhibiting the rapid sodium influx. Under suitable conditions these agents also can block the sodium channels of nerve fibers, which explains the localanesthetic effect of class I agents. 65 Class IA antiarrhythmic agents (QUINIDINE, NORPACE, PRONESTYL) • Lengthens refractory period, decrease automaticity, slows overall conduction via: • inhibition of the fast sodium channels • prolongation of the action potential by inhibiting the repolarizing K+ current Myocardial Action Potential Quinidine Effect • Indications: • treatment of supraventricular arrhythmias and supraventricular tachycardias • conversion of atrial fibrillation and atrial flutter to sinus rhythm • prevention of PSVT (Paroxysmal supraventricular tachycardia) • prevent recurrent ventricular tachycardia 66 Quinidine It is the prototype of class I antiarrhythmics (class Ia), therefore substances in this group also called “Quinidine-like”. – Quinidine is a dextrorotatory diastereoisomer of quinine. Both quinidine and quinine are obtained from many species of Cinchona plant. – Quinidine contains two basic nitrogens, of which the quinuclidine nitrogen has a pKa of ~10 and is thus more basic. –Quinidine is a prototypic anti-arrhythmic drug that reduces Na+ ion current by binding to the open ion channel resulting in depression of automaticity of ectopic foci. –It is used to treat supraventricular and ventricular ectopic arrhythmias, atrial and ventricular tachycardia, atrial flutter and atrial fibrillation. 67 Procainamide HCl NH N C NH2 O 4-amino-N-(2-(diethylamino)ethyl)benzamide A class Ia antiarrhythmic agent, has all the electrophysiological effects of quinidine. It is commonly prescribed by clinicians for ventricular tachycardias while quinidine for atrial arrhythmias . The major metabolite is N-acetylprocainamide (NAPA) which possesses only 25% activity of the parent compound. O NH N C O 68 NAPA N H N-Substituted carboxamides N-Substituted carboxamides have three common features: 1. A lipophilic aromatic group. 2. An aliphatic spacer group 3. A substituted amino group Lipophilicity is crucial for nonspecific interaction with the alkyl chains of the membrane’s phospholipids. Together with the amino group which can be protonated at physiological pH values. This seems to be the molecular requirement for antiarrhythmic activity of this group of compounds. Disopyramide (Class 1a) O C (RS)-4-[bis(1-methylethyl)amino]-2-phenyl-2-(pyrid- 2-yl)butyramide 69 N NH2 N Class I B antiarrhythmic agents ( XYLOCAINE (LIDOCAINE), MEXITIL, DILANTIN ) • Depresses automaticity in ectopic beats via: • inhibition of fast sodium channels, decrease action potential duration • works especially well in hyperkalemic (ischemic) myocardium & during MI • sometimes given prophylactically in acute MI • Indications: Myocardial Action Potential Lidocaine Effect • first line of treatment for acute ventricular arrhythmias • along with Class III drug Amiodarone – sometimes administered first • also used in ventricular arrhythmias associated with cardiac surgery 70 CH3 Lidocaine HCl O N N H CH3 2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide •A class Ib antiarrhythmic agent with a different effect on electrophysiological properties of myocardial cells from that of quinidine and procainamid. • Its administration is limited to the parenteral route. • It is rapidly metabolized in first pass metabolism. The monoethylglycinexylidide metabolite, resulting from partial deethylation of the N-diethyl group, is an effective anti-arrhythmic agent. • Its half-life ranging from 15-30 minutes and has a rapid onset of action. 71 Phenytoin O H N N H It is a class Ib antiarrhythmic agent used in treatment of digitalisinduced arrhythmias. Its action is similar to that of lidocaine. O 5,5-diphenylimidazolidine-2,4-dione Mexiletine.HCl (RS)-[2-(2,6-dimethylphenoxy)-1-methyl-ethyl]amine hydrochloride A class Ib antiarrhythmic agent which is effective both parenterally and orally. It may be used for chronic treatment. 72 Flecainide (Benzamide derivative) O F3C N-[(RS)-(piperidin-2-ylmethyl)]-2,5-bis(2,2,2trifluoroethoxy)benzamide O N H HN O CF3 It is a class Ic antiarrhythmic agent which is effective both parenterally and orally. Aprindine N 73 N It is a class Ic antiarrhythmic agent which has a sustained activity, however, due to the serious side effects (agranulocytosis) it should only be used for life-threatening arrhythmias 3.2. Class II antiarrhythmic agents (-receptor blockers) Propranolol Acebutolol Esmolol Satalol 74 3.3. Class III antiarrhythmic agents Agents in this class prolong the duration of action potential without changing its rate of rise. Amidarone O A class III drug used only in the treatment of documented life-threatening recurrent ventricular arrhythmias refractory to other agents. I O N O I Bretylium tosylate Br H3C N SO3 2-Bromobenzyl(ethyl)dimethylammonium toluene-4-sulfonate It is an adrenergic neuronal blocking agent that accumulates in the neurons and displaces norepinephrine. Because of this it was earlier used as an antihypertensive agent, but its use was discontinued due to development of tolerance and pain related side effects. 75 3.4. Class IV: Calcium Channel Blockers They are applied chiefly in coronary heart disease. Some of these substances also are used as antiarrhythmic therapy. Their antiarrhythmic effect is based on prolongation of the impulse conduction in the AV node and to a lower degree on inhibition of the impulse generation in the sinus node. In addition to class IV effects, it also shows class I effect. Bepridil Diltiazem Verapamil 76 4. Drugs used in Congestive Heart Failure Congestive Heart Failure • Cardiac failure can be described as the inability of the heart to pump blood effectively at a rate that meets the needs of the metabolizing tissues. • Increasing the force of contraction of the heart (positive inotropic activity) is very important for most heart failure patients. • There are several mechanisms by which this could be achieved including: 1. 2. Cardiac glycosides which are the most useful. Phosphodiesterase inhibitors, such as amrinone and milrinone. 3. Direct adenylate cyclase stimulants, such as forskolin (will not be discussed). 77 4.1. Cardiac Glycosides. Mode of Action The most widely accepted mechanism involves the ability of cardiac glycosides to inhibit the membrane bound Na+-K+-ATPase pump responsible for Na+-K+ exchange. Structure 78 The R group at the 17-position defines the class of cardiac glycoside. Two classes have been observed in Nature: 1. The cardenolides have an unsaturated butyrolactone ring. 2. The bufadienolides have an -pyrone ring (not used therapeutically due to high toxicity). 79 Nomenclature : The term 'genin' at the end refers to only the aglycone portion (without the sugar). Thus the word digitoxin refers to a agent consisting of digitoxigenin (aglycone) and sugar moieties (three). 80 The aglycone moiety: Rings A/B and C/D are cis fused while rings B/C are trans fused. Such ring fusion give the aglycone nucleus of cardiac glycosides the characteristic 'U' shape. 18-CH3 is cis to 14-OH and 19-CH3 is cis to 5-H whereas 8 and 9-Hs are trans to each other. 81 –The steroid nucleus has hydroxyls at 3- and 14- positions of which the sugar attachment uses the 3-OH group. 14-OH is normally unsubstituted. –Additional hydroxyl groups at 12- and 16- positions are greatly affect the duration of action. – The lactone moiety at C-17 position is an important structural feature. – Plant sources provide a 5-membered unsaturated lactone – Animal sources give a 6-membered unsaturated lactone. Sugar moiety : RIII 12 RIV 11 13 14 2 3 HO 17 16 15 RII 9 1 10 4 RI 5 6 8 7 OH H – One to 4 sugars are found to be present in most cardiac glycosides attached to the 3-OH group. – The sugars most commonly used include L-rhamnose, D-glucose, D- digitoxose, D-digitalose, D-digginose, D-sarmentose, L-vallarose, and D-fructose. 82 SAR 1. The sugar moiety appears to be important only for the partitioning and kinetics of action. It possesses no biological activity. 2. The "backbone" U shape of the steroid nucleus appears to be very important. Structures with C/D trans fusion are inactive. 3. Conversion to A/B trans system leads to a marked drop in activity. Thus although not mandatory A/B cis fusion is important. 4. The 14 -OH groups is now believed to be dispensible. A skeleton without 14 -OH group but retaining the C/D-cis ring fusion was found to retain activity. 5. Lactones alone, when not attached to the steroid skeleton, are not active. Thus the activity rests in the steroid skeleton. 83 SAR (Cont.) 6. The unsaturated 17-lactone plays an important role in receptor binding. Saturation of the lactone ring dramatically reduced the biological activity. 7. The lactone ring is not absolutely required. For example, using ,-unsaturated nitrile (C=C-CN group) the lactone could be replaced with little or no loss in biological activity. 84 4.2. Phosphodiesterase inhibitors Phosphodiesterases are responsible for the degradation of cyclic adenosine monophosphate (cAMP). Inhibition of these enzymes lead to increase the concentration of cAMP and the Ca2+ level in the myocardial cell. – Phosphodiesterase inhibitors have positive inotropic and vasodilatory properties thus they are effective in the treatment of acute cardiac failure. – 85 Amrinone NH2 N O NH 5-Amino-(3,4’-bipyridine)-6(1H)one It improve cardiac performance by enhancing cardiac contractility. It is used through i.v. route with strong restrictions. – Side Effects: Thrombocytopenia, hepatotoxicity, arrhythmia, nausea, vomiting and may lead to mortality due to heart failure by long term administration. 86 Milrinone CN N O NH H3C 5-Cyano-2-methyl-(3,4’-bipyridine)-6(1H)one It is about 10-30 times more potent than amrinone with a higher level of side effects that limit its use to acute therapy. – 87